Melanoma Clinical Trials
Find clinical trials for melanoma. Search for melanoma clinical trials in different cities and states across the United States.
Vemurafenib & MetforminA Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
Sponsor:
University of Louisville
Location:
Code:
NCT01638676
Conditions
Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Vemurafenib
Metformin
SX-682 with PembrolizumabSX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Sponsor:
Syntrix Biosystems, Inc.
Location:
Code:
NCT03161431
Conditions
Melanoma Stage III
Melanoma Stage IV
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
SX-682
Pembrolizumab
Radiotherapy & ImmunotherapyPRISM: Pre-Operative Radiotherapy and Immunotherapy for Sinonasal Melanoma
Sponsor:
M.D. Anderson Cancer Center
Location:
Code:
NCT05546827
Conditions
Sinonasal Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Surgical resection
CRX100 & PembrolizumabStudy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Sponsor:
BioEclipse Therapeutics
Location:
Code:
NCT04282044
Conditions
Solid Tumor, Adult
Triple Negative Breast Cancer
Colorectal Cancer
Hepatocellular Carcinoma
Osteosarcoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CRX100 suspension for infusion
Fludarabine
Cyclophosphamide
BAY3375968 & PembrolizumabA First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Sponsor:
Bayer
Location:
Code:
NCT05537740
Conditions
Advanced Solid Tumors
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BAY3375968
Pembrolizumab
HLA TestingA Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
Sponsor:
TScan Therapeutics, Inc.
Location:
Code:
NCT05812027
Conditions
Head and Neck Cancer
Cervical Cancer
Non Small Cell Lung Cancer
Melanoma
Ovarian Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Tumor and HLA Profiling
Naporafenib & TrametinibA Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Sponsor:
Erasca, Inc.
Location:
Code:
NCT06346067
Conditions
Advanced or Metastatic NRAS-mutant Melanoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Naporafenib
Dacarbazine
Temozolomide
Trametinib
Fianlimab & CemiplimabA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Sponsor:
Regeneron Pharmaceuticals
Location:
Code:
NCT05608291
Conditions
Melanoma
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Fianlimab
Cemiplimab
Pembrolizumab
Placebo
Fianlimab, Cemiplimab, IpilimumabA Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Sponsor:
Memorial Sloan Kettering Cancer Center
Location:
Code:
NCT06594991
Conditions
Advanced Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Fianlimab
Cemiplimab
Ipilimumab
AB248 & PembrolizumabA Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
Sponsor:
Asher Biotherapeutics, Inc.
Location:
Code:
NCT05653882
Conditions
Solid Tumor
Non Small Cell Lung Cancer
Melanoma
Squamous Cell Carcinoma of Head and Neck
Renal Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
etakafusp alfa (AB248)
pembrolizumab